ASH 2014 GvHD Plenary Wei Li

Top 5 Highlights of ASH 2014

At the annual meeting of the recent American Society of Hematology (ASH) in San Francisco there was a wealth of new information and data for consumption. At the risk of ignoring a lot compelling clinical data, Daedalus would like offer up five highlights from the meeting. Whether these are “top” is entirely a subjective and […]

Continue Reading
National Harbor MD

What’s Exciting in Cancer Immunotherapy?

A record attendance of over 1500 attendees went to the annual meeting of the Society for Immunotherapy of Cancer (SITC) last weekend at National Harbor in Maryland to hear about the latest developments in cancer immunotherapy. Cancer immunotherapy is about harnessing the body’s immune system to fight cancer. It is the hottest area in cancer […]

Continue Reading
Genentech PDL1 Video

The Promise of PD1 PDL1 Immunotherapy

The immune system is used to dealing with foreign invaders such as bacteria and pathogens. One of the challenges it faces with cancer is that tumor cells are basically a proliferation of human (self) cells gone awry. The result is it doesn’t recognize them as foreign very well because the mutations and aberrations are in […]

Continue Reading
Miami Beach Lifeguard Tower

Immuno-Oncology drives Pharma Licensing Strategy

Cancer immunotherapy, the ability to harness the body’s own immune system to fight cancer, is showing so much promise that it is driving Pharma corporate strategy. If you don’t have an immuno-oncology pipeline, including a checkpoint inhibitor in development, you may need to go out and find one, that’s the message from this week’s Pharma […]

Continue Reading
Autumn Leaves

Fall 2014 Cancer Conferences to Watch Out for

The leaves are turning and the weather is getting cooler in many parts of the country, so what are some of the cancer conferences to watch out for before the year end? On Biotech Strategy Blog we’ll be writing about four major medical and scientific meetings including SITC 2014 in Maryland, EORTC-NCI-AACR Molecular Targets in […]

Continue Reading
ESMO 2014 Congress - Madrid, Spain

ESMO 2014 Conference Coverage

The ESMO 2014 Congress takes place in Madrid at the end of September (Sept 26 -30) and we are already planning our conference coverage. Sadly, the ESMO and ECCO annual meetings have moved in a negative direction with this year’s meeting excluding nurses, patient advocates and media from the exhibit hall and industry satellite symposia, […]

Continue Reading
Greenwich London

Do you have a fast to market oncology new products strategy?

Pharma marketing strategy is a key part of every consulting project we do, whether it be a landscape report, thought leader market research or identifying target opportunities for oncology and hematology new products. We are constantly on the look out for fast-to-market strategies in market segments with high unmet medical need where emerging science and […]

Continue Reading
Cellectis CSO Phillippe Duchateau and CEO André Choulika

Who will win CAR-T cell immunotherapy race to market?

Chimeric Antigen Receptor T cell immunotherapy (known as CAR-T or more colloquially as CART)  has been in the news recently. Novartis/UPenn announced they received Breakthrough Therapy Designation (BTD) from the US Food & Drug Administration (FDA) for their CTL019 product in relapsed/refractory acute lymphocytic leukemia (ALL). Dr Stephen Grupp from The Children’s Hospital of Philadelphia […]

Continue Reading
Dr Sally Church ASCO 2014

ASCO 2014 Immuno-Oncology Review

Immuno-oncology was one of the hot topics in cancer drug development at ASCO 2014. Readers may recall my ASCO 2013 preview video that highlighted the significance of data for immune checkpoint inhibitors – this was when anti PD-1, PD-L1 compounds were generally not on many people’s radar. One thing we work hard at is picking […]

Continue Reading
Dr Janne AZD9291 Interview ASCO 2014

AstraZeneca AZD9291 shows lung cancer promise at ASCO 2014

The annual pilgrimage for cancer drug development professionals to ASCO (the annual meeting of the American Society of Clinical Oncology) in Chicago is over, and now we have to digest the tsunami of data such meetings create. The challenge with conferences such as these is not obtaining access to data – most of it is […]

Continue Reading